portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 Sinovac to Participate in Four Investor Conferences in September 2011
 
CreateTime:2011-08-31 Editor:lile
Text Size:       
 

BEIJING, Aug. 30, 2011  Sinovac Biotech Ltd. (SVA.NSDQ)a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, Ms. Nan Wang, Interim Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to attend four upcoming investor conferences in New York City and Boston.

Rodman & Renshaw Annual Global Investment Conference, New York City

Sinovac is scheduled to present at 2:50 pm on Monday, September 12, 2011 and will be participating in one-on-one meetings on September 12, 2011.

Morgan Stanley Global Healthcare Conference, New York City

Sinovac is scheduled to present at 1:35 pm ET on Tuesday, September 13, 2011 and will be participating in one-on-one meetings on September 13 and 14, 2011.

A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .

Morgan Stanley China Healthcare Day Conference, Boston

Sinovac will be participating in one-on-one meetings on Thursday, September 15, 2011

UBS Global Life Sciences Conference, New York City

Sinovac is scheduled to present at 4:00 pm ET on Monday, September 19, 2011 and will be participating in one-on-one meetings on September 19, 2011.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against hand, foot & mouth disease), mumps, rubella, HIB, epidemic meningitis, varicella and human rabies. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, which is anticipated to be launched in 2011.

 


Related Reports
China Independent Clinical Laboratory Industry Report, 2019-2025
Global and China Industrial Enzyme Industry Report, 2014-2017
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1